Tibet Rhodiola Pharmaceutical Holding Co (600211) — Cash Flow-to-Debt Ratio
Tibet Rhodiola Pharmaceutical Holding Co (600211) has a Cash Flow-to-Debt Ratio of 0.14x as of December 2025, meaning its operating cash flow of CN¥297.86 Million could theoretically repay 0% of its total liabilities (CN¥2.10 Billion) in one year. Explore 600211 strategic capital deployment ratio to see how much of total assets are deployed in long-term investments.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Tibet Rhodiola Pharmaceutical Holding Co Cash Flow-to-Debt Ratio (1999–2025)
Historical debt coverage capacity for Tibet Rhodiola Pharmaceutical Holding Co across 27 annual periods. Also explore total assets of Tibet Rhodiola Pharmaceutical Holding Co for the complete picture of this company's asset base.
Annual Cash Flow-to-Debt Ratio for Tibet Rhodiola Pharmaceutical Holding Co (1999–2025)
Year-by-year debt coverage analysis for Tibet Rhodiola Pharmaceutical Holding Co. For market capitalisation and broader financial context, see how much is Tibet Rhodiola Pharmaceutical Holding Co worth.
| Year | CF-to-Debt Ratio | Operating CF (CNY) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 0.49x | CN¥1.03 Billion | CN¥2.10 Billion | ▼ -60.9% |
| 2024 | 1.25x | CN¥994.79 Million | CN¥795.23 Million | ▲ +40.3% |
| 2023 | 0.89x | CN¥1.08 Billion | CN¥1.21 Billion | ▲ +13.8% |
| 2022 | 0.78x | CN¥837.38 Million | CN¥1.07 Billion | ▲ +147.5% |
| 2021 | 0.32x | CN¥366.53 Million | CN¥1.16 Billion | ▼ -73.7% |
| 2020 | 1.20x | CN¥428.17 Million | CN¥355.91 Million | ▼ -21.3% |
| 2019 | 1.53x | CN¥489.59 Million | CN¥320.44 Million | ▲ +45.2% |
| 2018 | 1.05x | CN¥289.22 Million | CN¥274.89 Million | ▲ +227.4% |
| 2017 | 0.32x | CN¥91.46 Million | CN¥284.64 Million | ▲ +109.6% |
| 2016 | 0.15x | CN¥250.21 Million | CN¥1.63 Billion | ▼ -74.8% |
| 2015 | 0.61x | CN¥133.93 Million | CN¥220.43 Million | ▲ +371.7% |
| 2014 | -0.22x | CN¥-141.40 Million | CN¥632.26 Million | ▼ -159.1% |
| 2013 | 0.38x | CN¥279.22 Million | CN¥738.26 Million | ▲ +209.4% |
| 2012 | 0.12x | CN¥56.20 Million | CN¥459.72 Million | ▲ +337.8% |
| 2011 | 0.03x | CN¥12.09 Million | CN¥432.93 Million | ▲ +504.5% |
| 2010 | 0.00x | CN¥1.90 Million | CN¥411.28 Million | ▼ -88.5% |
| 2009 | 0.04x | CN¥17.88 Million | CN¥443.70 Million | ▲ +3.4% |
| 2008 | 0.04x | CN¥21.46 Million | CN¥550.51 Million | ▲ +218.8% |
| 2007 | -0.03x | CN¥-18.30 Million | CN¥557.68 Million | ▼ -145.9% |
| 2006 | 0.07x | CN¥33.63 Million | CN¥470.56 Million | ▲ +61.4% |
| 2005 | 0.04x | CN¥18.92 Million | CN¥427.37 Million | ▼ -43.8% |
| 2004 | 0.08x | CN¥26.90 Million | CN¥341.74 Million | ▼ -45.0% |
| 2003 | 0.14x | CN¥47.20 Million | CN¥329.82 Million | ▲ +36.9% |
| 2002 | 0.10x | CN¥32.85 Million | CN¥314.23 Million | ▲ +36.4% |
| 2001 | 0.08x | CN¥15.47 Million | CN¥201.82 Million | ▼ -53.0% |
| 2000 | 0.16x | CN¥20.55 Million | CN¥126.01 Million | ▲ +239.2% |
| 1999 | 0.05x | CN¥2.25 Million | CN¥46.73 Million | — |